If You Invested in Puma Biotechnology Inc (PBYI)

Puma Biotechnology, Inc. (NASDAQ: PBYI) is a biopharmaceutical company focused on the development and commercialization of products to enhance cancer care. According to the company’s public disclosures, Puma’s strategy centers on targeted therapies in oncology, with an emphasis on HER2-positive and HER2-negative breast cancer and small cell lung cancer. The company’s shares trade on the Nasdaq Global Select Market under the ticker symbol PBYI.

Core business and oncology focus

Puma Biotechnology describes itself as a biopharmaceutical company with a focus on developing and commercializing products intended to improve treatment outcomes for cancer patients. The company in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, an oral kinase inhibitor, is the active ingredient in Puma’s first commercial product, NERLYNX® (neratinib) tablets.

NERLYNX has multiple regulatory approvals. The U.S. Food and Drug Administration (FDA) approved oral neratinib in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed or amplified breast cancer following adjuvant trastuzumab-based therapy. Puma states that this product is marketed in the United States as NERLYNX (neratinib) tablets. In February 2020, the FDA also approved NERLYNX in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

In Europe, NERLYNX received marketing authorization from the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive, HER2-overexpressed or amplified breast cancer who are less than one year from completion of prior adjuvant trastuzumab-based therapy. These indications frame Puma’s commercial focus on HER2-driven breast cancer in both early-stage and metastatic settings.

NERLYNX and revenue profile

Puma reports that product revenue, net consists entirely of sales revenue from NERLYNX, its first commercial product. In its public financial updates, the company distinguishes between product revenue, net from NERLYNX sales and royalty revenue related to its licensing arrangements. This underscores the central role of NERLYNX in Puma’s current commercial operations.

The company has also implemented the Puma Patient Lynx support program to help ensure patients have access to NERLYNX. According to Puma, this program assists patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. This patient support infrastructure reflects Puma’s focus on facilitating real-world use of its oncology therapy.

Alisertib development programs

Beyond NERLYNX, Puma is developing alisertib, an anti-cancer drug described as a selective, small molecule, orally administered inhibitor of aurora kinase A. In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of alisertib. The company states that it initially intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer.

Puma has initiated multiple Phase II clinical trials under the ALISCA™ program. In February 2024, the company started ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, hormone receptor-positive metastatic breast cancer. These trials illustrate Puma’s efforts to expand its oncology pipeline beyond HER2-positive disease into additional breast cancer subtypes and small cell lung cancer.

Regulatory and index inclusion

Puma Biotechnology has highlighted several milestones that frame its position within the biotechnology and pharmaceutical sector. The company reports that it has been added to the Nasdaq Biotechnology Index (NBI), which is designed to track the performance of biotechnology and pharmaceutical securities listed on The Nasdaq Stock Market that meet certain eligibility requirements, including minimum market capitalization, trading volume, and seasoning as a public company. Inclusion in this index reflects that Puma meets these Nasdaq-defined criteria.

The company’s regulatory disclosures also show that it files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), including Forms 8-K related to financial results and corporate governance matters. For example, Puma has filed 8-K reports to furnish quarterly financial results and to disclose amendments to its bylaws.

Corporate governance and listing

Puma Biotechnology is incorporated in Delaware and lists its common stock on the Nasdaq Global Select Market. The company’s board of directors and its committees, including a Compensation Committee, oversee matters such as equity incentive awards. Puma has adopted a 2017 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees as inducements to join the company, in accordance with Nasdaq Listing Rule 5635(c)(4). Public announcements describe recurring grants of inducement restricted stock unit awards to non-executive employees under this plan, with vesting schedules over three years, subject to continued service.

In June 2025, the board of directors approved and adopted an amendment and restatement of Puma’s Fourth Amended and Restated Bylaws, primarily to revise provisions in order to be more in line with updates to Delaware law and to incorporate related conforming and ministerial changes. This illustrates ongoing attention to corporate governance and compliance with evolving legal frameworks.

Financial reporting and operations

Puma Biotechnology regularly reports its financial results, including product revenue, royalty revenue, operating costs and expenses, research and development expenses, and net income or loss. The company provides both GAAP and non-GAAP adjusted metrics, with non-GAAP adjusted net income excluding stock-based compensation expenses. Puma also reports cash flows from operating activities and discloses cash, cash equivalents and marketable securities balances.

In its financial communications, Puma attributes changes in revenue and expenses to factors such as NERLYNX sales volumes, royalty revenue trends, timing of product supply to international licensees, gross-to-net adjustments, legal fees, and increased alisertib study activity. The company also offers financial outlook ranges for revenue and net income, while noting that forward-looking statements are subject to risks and uncertainties.

Therapeutic indications and safety information

Puma provides detailed prescribing and safety information for NERLYNX. The product is indicated as a single agent for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer to follow adjuvant trastuzumab-based therapy. It is also indicated in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

The company’s disclosures outline important safety information, including warnings and precautions related to diarrhea, hepatotoxicity, and embryo-fetal toxicity, as well as common adverse reactions and drug interaction considerations. While these details are directed primarily to healthcare professionals and patients, they also underscore the regulatory and clinical framework within which Puma operates.

Position within the pharmaceutical preparation manufacturing industry

Within the broader pharmaceutical preparation manufacturing sector, Puma Biotechnology is characterized by its focus on oncology and targeted small-molecule therapies. The company’s business model, as described in its public communications, combines commercialization of an approved cancer therapy (NERLYNX) with clinical development of additional oncology candidates such as alisertib. Revenue is derived from product sales and royalties linked to NERLYNX, while research and development spending supports pipeline advancement.

Investors and analysts interested in PBYI stock often review Puma’s regulatory approvals, clinical trial progress, index membership, and financial performance to understand the company’s role in the biopharmaceutical landscape. Because Puma’s activities are concentrated in cancer care, developments in its clinical programs, regulatory status, and commercialization efforts can be significant drivers of interest in the stock.

Key points for PBYI investors

• Puma Biotechnology is a Nasdaq-listed biopharmaceutical company focused on cancer care.
• The company in-licensed global rights to oral neratinib (PB272) in 2011 and markets it as NERLYNX for HER2-positive breast cancer in specified settings.
• NERLYNX has FDA approval in the United States and marketing authorization in the European Union for defined early-stage and metastatic breast cancer indications.
• Product revenue, net consists entirely of sales revenue from NERLYNX, supplemented by royalty revenue.
• Puma is developing alisertib, a selective, orally administered inhibitor of aurora kinase A, under Phase II ALISCA trials in small cell lung cancer and HER2-negative, hormone receptor-positive metastatic breast cancer.
• The company is included in the Nasdaq Biotechnology Index, reflecting its classification as a biotechnology or pharmaceutical issuer that meets Nasdaq’s eligibility criteria.
• Puma maintains corporate governance practices that include an inducement equity award plan for new employees and periodic updates to its bylaws.